Skip to main content

Research: Systems cancer biology and immunology, cancer therapeutic response, protein-protein interaction networks (interactomes), post-translational modifications, epigenetic regulation, signal transduction, disease marker discovery.

Xian Chen

Xian Chen

Professor of Biochemistry and Biophysics
Faculty Director, Quantitative Proteomics Center for Disease Marker Discovery
(PhD – Penn State University)


Xian Chen is a Professor at the Department of Biochemistry and Biophysics at -CH, Faculty Director for -Duke Michael Hooker Proteomics Center, and a member of Lineberger NCI Comprehensive Cancer Center. He completed his B.S. undergraduate degree in Chemistry for Peking (Beijing) University, China. He then came to US to obtain his Ph.D. in Physical Organic Chemistry from the Penn State University. Followed by a two-year postdoctoral training in the field of molecular biology and enzymology at University of Florida Health Science Center, he joined Life Science Division, Los Alamos National Lab, first as a postdoctoral fellow studying in multi-dimensional structures of DNA and proteins primarily using NMR, later he became a staff member and then was promoted to the Leader of a bioanalytical team. He joined the -Chapel Hill faculty in late 2006.  Because of his multi-disciplinary training background, Dr. Chen has broad research interests cross biochemistry, biophysics, genetics, and biology, with an emphasis on studies of systems dysregulation of cellular signaling and functional pathways in diseases. His research group in conjunction with the technology development mission at the Proteomics Center also focus on developing novel techniques capable of performing systems investigation to address ‘real-world’ biological concerns in more sensitive, precise, and high throughput way.

Trained Faculty Mentor endorsed by Office of Graduate Ed  Chapel Hill

HONORS & AWARDS

  • The 2001 Patent & Licensing Awards, Los Alamos National Lab, 2002
  • Presidential Early Career Award for Scientists and Engineers (PECASE), 1999
  • Department of Energy Early Career Award for Scientists and Engineers, 1999

RESEARCH

Our research focuses on both developments and applications of unconventional and transformative technology of systems biology, novel mass spectrometry-based proteomics and proteogenomics approaches in particular, to elucidate the molecular mechanisms underlying pathogenesis of various human diseases such as cancer, asthma, and immune disorders. We are interested in a broad range of signaling and epigenetic regulatory pathways/mechanisms underlying exactly how tumor cells escape from immune surveillance, but not limited to the Toll-like receptor (TLR)-mediated pathways and DNA damage response pathways. Our ultimate goal is to mechanistically derive novel, precise disease markers for early diagnosis and therapeutic intervention.

As the Director of Technology Development in Proteomics Center, Dr. Chen has an innovative track record in developing an array of new proteomic and proteogenomic technologies for both discovery and clinical application in cancer biology and immunology. He is also the PI of the NCI Clinical Proteomic Tumor Analysis Consortium (CPTAC). He has developed many novel MS-based quantitative proteomic methods; he invented amino acid-coded mass tagging (AACT) (a.k.a SILAC) that has unique strengths for comparative analysis of protein-protein interactions and post-translational protein modification. The Chen lab has demonstrated the unique strength of quantitative proteomics in dissecting and discovering new pathways involved in immune/inflammatory signaling and cancer epigenetic regulation.

PUBLICATIONS

NEWS

Xian Chen PhD featured on The Proteomics Show podcast “Road to Chicago” series (Dec. 2022)

Lab Contact

Lab Rooms: 3072 Genetic Medicine
Lab Phone: 919-966-7489
Fax: 919-966-2852